- 169. Pterinechemistry Part 84 A New, Regiospecific Synthesis of L-Biopterin
-
Pure L-biopterin was obtained in 42percent yield by the condensation of 5-deoxy-L-arabinose-phenylhydrazone-triacetate with 4-hydroxy-2,5,6-triaminopyrimidine, followed by iodine oxidation of the formed tetrahydropterin derivative to 1',2'-O-diacetyl-L-biopterin.Deacetylation was carried out with NH4OH.
- Schircks, Bernhard,Bieri, Jost H.,Viscontini, Max
-
-
Read Online
- Preparation method of sapropterin dihydrochloride
-
The invention relates to a preparation method of sapropterin dihydrochloride shown as formula (I) as shown in the specification. The preparation method comprises the steps of taking 5-deoxy arabinoseas a raw material, performing acetylation reaction in the presence of acetic anhydride to form an intermediate DL-1, allowing DL-1 to react with phenylhydrazine under the catalysis of acetic acid to form an intermediate DL-2, allowing DL-2 and pyrimidylamine sulfate to give a ring closing reaction under the catalysis of anhydrous lithium perchlorate to form an intermediate DL-3, directly oxidizingDL-3 through elemental iodine without purification to form an intermediate DL-4, hydrolyzing DL-4 through potassium hydroxide to form L-biopterin (DL-5), and reducing and salifying L-biopterin through a platinum catalyst to form sapropterin dihydrochloride. The preparation method is easy and simple to operate, high in yield, low in energy consumption and suitable for industrial production, the total yield of the preparation method is greater than 70%, and the purity of a final product reaches above 99.5%.
- -
-
Paragraph 0024
(2019/06/07)
-
- COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISEASES
-
The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II or formula III; and methods for treating or preventing metabolic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of phenylketonuria, cardiovascular disease, autism, ADHD, hypertension, endothelial dysfunction and chronic kidney disease.
- -
-
-
- Crystalline polymorph of biopterin and production method thereof
-
Crystalline solids A to E of biopterin are distinguished from each other by diffraction angle in an X-ray powder diffraction pattern measured using Cu—Kα radiation. The crystalline solid A is characterized by strong peak at 4.6° and peaks at 13.6°, 18.1° and 27.5°; the crystalline solid B is characterized by strong peak at 4.85° and peaks at 2.4°, 13.2°, 18.1° and 27.3°; the crystalline solid C is characterized by strong peak at 5.35° and peaks at 10.8°, 21.9° and 27.3°; the crystalline solid D is characterized by strong peak at 5.1° and peaks at 2.6°, 9.2°, 13.4°, 15.4°, 18.3°, 21.8° and 27.3°; and the crystalline solid E is characterized by strong peaks at 4.5° and 5.8°, and peaks at 10.6°, 15.6°, 20.0°, 20.7°, 23.8° and 27.3°.
- -
-
-
- Method for producing L-biopterin
-
To provide a method for producing L-biopterin on a large industrial scale by using a reagent which is inexpensive and easy to handle, without requiring a use of any particular equipment or plants.
- -
-
Page/Page column 5
(2008/06/13)
-